Edition:
United States

Oasmia Pharmaceutical AB (OASM.ST)

OASM.ST on Stockholm Stock Exchange

2.80SEK
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
2.80kr
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
518,826
52-wk High
9.63kr
52-wk Low
2.19kr

Chart for

About

Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company engaged in the field of human and veterinary oncology. The Company’s activities are divided into two segments: Human Health and Animal Health. The Human Health segment specializes in ovarian and breast cancer. The Animal Health area focuses on developing cancer... (more)
No analyst recommendations are available for .

Overall

Beta: 1.49
Market Cap(Mil.): kr493.94
Shares Outstanding(Mil.): 176.41
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.13 15.67
EPS (TTM): -- -- --
ROI: -- 15.10 34.62
ROE: -- 16.59 16.00

BRIEF-Oasmia receives marketing approval for Paclical in Kazakhstan

* OASMIA PHARMACEUTICAL RECEIVES MARKETING APPROVAL FOR PACLICAL® IN KAZAKHSTAN Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

Dec 11 2017

BRIEF-Oasmia Pharmaceutical Q2 operating loss shrinks

* OASMIA PHARMACEUTICAL AB Q2 ‍CONSOLIDATED NET SALES AMOUNTED TO TSEK 1,651 COMPARED TO TSEK 56 IN THE SECOND QUARTER THE PREVIOUS YEAR ​

Dec 01 2017

BRIEF-Oasmia completes 28 mln SEK private placement of new convertible instruments

* OASMIA HAS COMPLETED A PRIVATE PLACEMENT OF NEW CONVERTIBLE INSTRUMENTS IN A TOTAL AMOUNT OF SEK 28,000,000

Nov 30 2017

BRIEF-Oasmia CFO resigns

* Oasmia Pharmaceutical Ab Announces Resignation Of Its Chief Financial Officer

Oct 04 2017

BRIEF-Nexttobe extends loan to Oasmia Pharmaceutical

* Nexttobe extends loan to Oasmia Pharmaceutical Further company coverage: (Reporting by Stockholm Newsroom)

Oct 02 2017

BRIEF-Oasmia Q1 operating loss lower

* Says Q1 operating loss was TSEK 28,421 compared to TSEK 32,343 in Q1 previous year

Sep 01 2017

BRIEF-Oasmia Pharmaceutical says receives market approval for anti-cancer drug in Russia

* Receives Market Approval For Its Anti-cancer Drug Doxophos® in Russia Source text for Eikon: Further company coverage: (Reporting By Johan Sennero)

Aug 08 2017

BRIEF-Oasmia Pharmaceutical says through rights issue, its share capital up by 5 mln SEK to 17.6 mln SEK

* Says through rights issue, Oasmia's share capital increases by sek 5 million to sek 17.6 million

Jul 07 2017

BRIEF-Oasmia enters into marketing, distribution agreement concerning Russia, other markets

* Oasmia Pharmaceutical enters into new exclusive marketing and distribution agreement concerning Russia and other CIS markets

Jun 14 2017

BRIEF-Oasmia says enters into new marketing and distribution agreement for Russia and CIS

* Oasmia pharmaceutical enters into new exclusive marketing and distribution agreement concerning russia and other cis markets Source text for Eikon: Further company coverage: (Stockholm Newsroom)

Jun 14 2017

Earnings vs. Estimates